Amyloid Cardiomyopathy, Transthyretin-Related Clinical Trial
Official title:
A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
Up to 48 healthy volunteers will be given a single dose of AG10 or placebo and be monitored for safety and tolerability over a 5-day period. Up to 48 healthy volunteers will be given multiple doses of AG10 or placebo and be monitored for safety and tolerability over a 15-day period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04988386 -
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
|
Phase 3 | |
| Recruiting |
NCT03812172 -
Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
|